Prostate cancer

Kaustubh Datta, Donald J. Tindall

Research output: Chapter in Book/Report/Conference proceedingChapter

Abstract

Introduction Prostate cancer (PCa) is the most frequently diagnosed, and the second leading cause of death from cancer in North American and European men (1). It has the highest incidence rate among all epithelial tumors in the United States. Approximately 1 in 6 men over the age of 65 is diagnosed with PCa (2). Age, racial background, dietary factors, life-style related factors, and androgens are known contributors to the risk of PCa. Heterogeneity in PCa There is a high variability in the natural history of PCa ranging from indolent and asymptomatic to aggressive and metastatic disease. It is also multi-focal and heterogeneous in clinical, histological, and biological dispositions. Healthy glands, precursor, and neoplastic lesions with varying degrees of differentiation often exist in juxtaposition and evolve independently in the same PCa tissue (3,4). Prostate intra-epithelial neoplasia (PIN) is thought to be a precursor lesion for PCa. High-grade PIN with increased nuclear enlargement, prominent nucleoli, chromatin alterations, and luminal complexity in acinar epithelium is often detected together with PCa in biopsy samples (4,5). PIN shares many common genetic, molecular, and phenotypic characteristics of prostate adenocarcinoma (3,5). Gleason grade has been used to indicate the severity of the disease.AhigherGleason grade suggests a poorly diferentiated, advanced carcinoma and is used as a prognostic indicator (4).

Original languageEnglish (US)
Title of host publicationMolecular Oncology
Subtitle of host publicationCauses of Cancer and Targets for Treatment
PublisherCambridge University Press
Pages591-597
Number of pages7
ISBN (Electronic)9781139046947
ISBN (Print)9780521876629
DOIs
StatePublished - Jan 1 2015

Fingerprint

Prostatic Neoplasms
Prostate
Neoplasms
Androgens
Chromatin
Life Style
Molecular Biology
Cause of Death
Adenocarcinoma
Epithelium
Carcinoma
Biopsy
Incidence

ASJC Scopus subject areas

  • Medicine(all)

Cite this

Datta, K., & Tindall, D. J. (2015). Prostate cancer. In Molecular Oncology: Causes of Cancer and Targets for Treatment (pp. 591-597). Cambridge University Press. https://doi.org/10.1017/CBO9781139046947.053

Prostate cancer. / Datta, Kaustubh; Tindall, Donald J.

Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, 2015. p. 591-597.

Research output: Chapter in Book/Report/Conference proceedingChapter

Datta, K & Tindall, DJ 2015, Prostate cancer. in Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, pp. 591-597. https://doi.org/10.1017/CBO9781139046947.053
Datta K, Tindall DJ. Prostate cancer. In Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press. 2015. p. 591-597 https://doi.org/10.1017/CBO9781139046947.053
Datta, Kaustubh ; Tindall, Donald J. / Prostate cancer. Molecular Oncology: Causes of Cancer and Targets for Treatment. Cambridge University Press, 2015. pp. 591-597
@inbook{1b4075eb9ef14687b620edceeb70ace4,
title = "Prostate cancer",
abstract = "Introduction Prostate cancer (PCa) is the most frequently diagnosed, and the second leading cause of death from cancer in North American and European men (1). It has the highest incidence rate among all epithelial tumors in the United States. Approximately 1 in 6 men over the age of 65 is diagnosed with PCa (2). Age, racial background, dietary factors, life-style related factors, and androgens are known contributors to the risk of PCa. Heterogeneity in PCa There is a high variability in the natural history of PCa ranging from indolent and asymptomatic to aggressive and metastatic disease. It is also multi-focal and heterogeneous in clinical, histological, and biological dispositions. Healthy glands, precursor, and neoplastic lesions with varying degrees of differentiation often exist in juxtaposition and evolve independently in the same PCa tissue (3,4). Prostate intra-epithelial neoplasia (PIN) is thought to be a precursor lesion for PCa. High-grade PIN with increased nuclear enlargement, prominent nucleoli, chromatin alterations, and luminal complexity in acinar epithelium is often detected together with PCa in biopsy samples (4,5). PIN shares many common genetic, molecular, and phenotypic characteristics of prostate adenocarcinoma (3,5). Gleason grade has been used to indicate the severity of the disease.AhigherGleason grade suggests a poorly diferentiated, advanced carcinoma and is used as a prognostic indicator (4).",
author = "Kaustubh Datta and Tindall, {Donald J.}",
year = "2015",
month = "1",
day = "1",
doi = "10.1017/CBO9781139046947.053",
language = "English (US)",
isbn = "9780521876629",
pages = "591--597",
booktitle = "Molecular Oncology",
publisher = "Cambridge University Press",

}

TY - CHAP

T1 - Prostate cancer

AU - Datta, Kaustubh

AU - Tindall, Donald J.

PY - 2015/1/1

Y1 - 2015/1/1

N2 - Introduction Prostate cancer (PCa) is the most frequently diagnosed, and the second leading cause of death from cancer in North American and European men (1). It has the highest incidence rate among all epithelial tumors in the United States. Approximately 1 in 6 men over the age of 65 is diagnosed with PCa (2). Age, racial background, dietary factors, life-style related factors, and androgens are known contributors to the risk of PCa. Heterogeneity in PCa There is a high variability in the natural history of PCa ranging from indolent and asymptomatic to aggressive and metastatic disease. It is also multi-focal and heterogeneous in clinical, histological, and biological dispositions. Healthy glands, precursor, and neoplastic lesions with varying degrees of differentiation often exist in juxtaposition and evolve independently in the same PCa tissue (3,4). Prostate intra-epithelial neoplasia (PIN) is thought to be a precursor lesion for PCa. High-grade PIN with increased nuclear enlargement, prominent nucleoli, chromatin alterations, and luminal complexity in acinar epithelium is often detected together with PCa in biopsy samples (4,5). PIN shares many common genetic, molecular, and phenotypic characteristics of prostate adenocarcinoma (3,5). Gleason grade has been used to indicate the severity of the disease.AhigherGleason grade suggests a poorly diferentiated, advanced carcinoma and is used as a prognostic indicator (4).

AB - Introduction Prostate cancer (PCa) is the most frequently diagnosed, and the second leading cause of death from cancer in North American and European men (1). It has the highest incidence rate among all epithelial tumors in the United States. Approximately 1 in 6 men over the age of 65 is diagnosed with PCa (2). Age, racial background, dietary factors, life-style related factors, and androgens are known contributors to the risk of PCa. Heterogeneity in PCa There is a high variability in the natural history of PCa ranging from indolent and asymptomatic to aggressive and metastatic disease. It is also multi-focal and heterogeneous in clinical, histological, and biological dispositions. Healthy glands, precursor, and neoplastic lesions with varying degrees of differentiation often exist in juxtaposition and evolve independently in the same PCa tissue (3,4). Prostate intra-epithelial neoplasia (PIN) is thought to be a precursor lesion for PCa. High-grade PIN with increased nuclear enlargement, prominent nucleoli, chromatin alterations, and luminal complexity in acinar epithelium is often detected together with PCa in biopsy samples (4,5). PIN shares many common genetic, molecular, and phenotypic characteristics of prostate adenocarcinoma (3,5). Gleason grade has been used to indicate the severity of the disease.AhigherGleason grade suggests a poorly diferentiated, advanced carcinoma and is used as a prognostic indicator (4).

UR - http://www.scopus.com/inward/record.url?scp=84954133624&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84954133624&partnerID=8YFLogxK

U2 - 10.1017/CBO9781139046947.053

DO - 10.1017/CBO9781139046947.053

M3 - Chapter

AN - SCOPUS:84954133624

SN - 9780521876629

SP - 591

EP - 597

BT - Molecular Oncology

PB - Cambridge University Press

ER -